You don’t know them until you challenge them – micro ribonucleic acid changes in response to acute exercise in patients with coronary artery disease

Abstract

Get full access to this article

View all access options for this article.

References

NCD Countdown 2030 Collaborators. NCD Countdown 2030: Worldwide trends in non-communicable disease mortality and progress towards Sustainable Development Goal target 3.4. Lancet 2018; 392: 1072–1088.

Townsend

Nichols

Scarborough

et al.

Cardiovascular disease in Europe – epidemiological update 2015. Eur Heart J 2015; 36: 2696–2705.

Chen

Luo

Wei

et al.

Altered plasma miR-144 as a novel biomarker for coronary artery disease. Ann Clin Lab Sci 2018; 48: 440–445.

Fichtlscherer

De Rosa

Fox

et al.

Circulating microRNAs in patients with coronary artery disease. Circ Res 2010; 107: 677–684.

Sun

Zhang

Sanagawa

et al.

Circulating microRNA-126 in patients with coronary artery disease: Correlation with LDL cholesterol. Thromb J 2012; 10: 16–16.

Yang

et al.

Circulating microRNAs as novel diagnostic biomarkers for very early-onset (</=40 years) coronary artery disease. Biomed Environ Sci 2016; 29: 545–554.

Mayr

Muller

Schafer

et al.

Exercise responsive micro ribonucleic acids identify patients with coronary artery disease. Eur J Prev Cardiol. 2019; 26: 348–355.

Leoncini

Bertaina

Papaioannou

et al.

MicroRNA fingerprints in juvenile myelomonocytic leukemia (JMML) identified miR-150-5p as a tumor suppressor and potential target for treatment. Oncotarget 2016; 7: 55395–55408.

Zhang

Liu

et al.

MiR-101-3p inhibits the growth and metastasis of non-small cell lung cancer through blocking PI3K/AKT signal pathway by targeting MALAT-1. Biomed Pharmacother 2017; 93: 1065–1073.

10.

Zhou

et al.

miR-101-3p suppresses HOX Transcript Antisense RNA (HOTAIR)-induced proliferation and invasion through directly targeting SRF in gastric carcinoma cells. Oncol Res 2017; 25: 1383–1390.

11.

Wang

et al.

miR-141-3p functions as a tumor suppressor modulating activating transcription factor 5 in glioma. Biochem Biophys Res Commun 2017; 490: 1260–1267.

12.

Cui

Zhu

et al.

MicroRNA-200b-3p suppresses epithelial-mesenchymal transition and inhibits tumor growth of glioma through down-regulation of ERK5. Biochem Biophys Res Commun 2016; 478: 1158–1164.

13.

Ishibashi

Akagi

Ogawa

et al.

MiR-141-3p is upregulated in esophageal squamous cell carcinoma and targets pleckstrin homology domain leucine-rich repeat protein phosphatase-2, a negative regulator of the PI3K/AKT pathway. Biochem Biophys Res Commun 2018; 501: 507–513.

14.

Hortmann

Walter

Benning

et al.

Droplet digital PCR of serum miR-499, miR-21 and miR-208a for the detection of functionally relevant coronary artery disease. Int J Cardiol 2018. pii: S0167-5273(18): 32300–32303. DOI: 10.1016/j.ijcard.2018.08.031.

15.

Pan

Liu

Zhou

et al.

Circular RNAs promote TRPM3 expression by inhibiting hsa-miR-130a-3p in coronary artery disease patients. Oncotarget 2017; 8: 60280–60290.

16.

Bildirici

Arslan

Ozbilum Sahin

et al.

MicroRNA-221/222 expression in atherosclerotic coronary artery plaque versus internal mammarian artery and in peripheral blood samples. Biomarkers 2018; 23: 670–675.

17.

Zhou

Yue

et al.

Interpreting the various associations of MiRNA polymorphisms with susceptibilities of cardiovascular diseases: Current evidence based on a systematic review and meta-analysis. Medicine (Baltimore) 2018; 97: e10712–e10712.

18.

Lee

Twerenbold

Tanglay

et al.

Clinical benefit of high-sensitivity cardiac troponin I in the detection of exercise-induced myocardial ischemia. Am Heart J 2016; 173: 8–17.